SHARE

Merck in advanced talks to buy Terns Pharma in $6bn oncology push

Merck is reportedly nearing an all-cash deal to acquire Terns Pharma for about $6bn to bolster its cancer pipeline as Keytruda faces patent expiry from 2028. The move follows recent buys of Verona Pharma for $10bn and Cidara Therapeutics for $9.2bn.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.